Two core platforms that unlock new possibilities in drug delivery

Focusing on developing transdermal and ocular drug-delivery systems, we break through the limitations of traditional formulations to enhance therapeutic efficacy and patient compliance.

505(b)(2) Pipeline

NO.
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
NDA
APPROVAL
EBP002
Alzheimer's Disease(7-day patch)
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approval
 
 
EBP006
Pulmonary Hypertension(1-day patch)
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approval
 
 
EBD008
Posterior Segment Diseases(Eye Drops)
Preclinical
Phase 1
Phase 2
Phase 3
NDA
Approval
 
 

High-Barrier Generic Drugs Pipeline

NO.
INDICATION
PRECLINICAL
BE STUDY
NDA
APPROVAL
EBP005
Schizophrenia(1-day patch)
Preclinical
BE Study
NDA
Approval
 
 
EBP007
Asthma/COPD(1-day patch)
Preclinical
BE Study
NDA
Approval
 
 
 

R&D Advantages of Transdermal Drug Delivery Systems:

  • Enhanced drug bioavailability
  • Improved dosing convenience
  • Reduced adverse reactions
  • Expanded therapeutic indications
  • Prolonged drug action duration

By developing new formulations through the 505(b)(2) regulatory pathway, we are able to:

  • Shorten development timelines
  • Reduce R&D risks
  • Accelerate time-to-market